|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:HMGN2-NECAB3 (FusionGDB2 ID:36786) |
Fusion Gene Summary for HMGN2-NECAB3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: HMGN2-NECAB3 | Fusion gene ID: 36786 | Hgene | Tgene | Gene symbol | HMGN2 | NECAB3 | Gene ID | 3151 | 63941 |
| Gene name | high mobility group nucleosomal binding domain 2 | N-terminal EF-hand calcium binding protein 3 | |
| Synonyms | HMG17 | APBA2BP|EFCBP3|NIP1|STIP3|SYTIP2|XB51|dJ63M2.4|dJ63M2.5 | |
| Cytomap | 1p36.11 | 20q11.22 | |
| Type of gene | protein-coding | protein-coding | |
| Description | non-histone chromosomal protein HMG-17high mobility group nucleosome-binding domain-containing protein 2high mobility group protein N2high-mobility group (nonhistone chromosomal) protein 17nonhistone chromosomal protein HMG-17 | N-terminal EF-hand calcium-binding protein 3EF-hand calcium binding protein 3Nek2-interacting protein 1X11L-binding protein 51amyloid beta (A4) precursor protein-binding, family A, member 2 binding proteinamyloid beta A4 protein-binding family A memb | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | P05204 | Q96P71 | |
| Ensembl transtripts involved in fusion gene | ENST00000361427, ENST00000493418, | ENST00000246190, ENST00000375238, ENST00000606525, | |
| Fusion gene scores | * DoF score | 9 X 4 X 4=144 | 7 X 4 X 4=112 |
| # samples | 8 | 7 | |
| ** MAII score | log2(8/144*10)=-0.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/112*10)=-0.678071905112638 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: HMGN2 [Title/Abstract] AND NECAB3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | HMGN2(26799118)-NECAB3(32248201), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | NECAB3 | GO:0019538 | protein metabolic process | 12780348 |
| Tgene | NECAB3 | GO:0042984 | regulation of amyloid precursor protein biosynthetic process | 10833507 |
| Fusion gene breakpoints across HMGN2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across NECAB3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | Non-Cancer | ERR315404 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - |
Top |
Fusion Gene ORF analysis for HMGN2-NECAB3 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000361427 | ENST00000246190 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - |
| In-frame | ENST00000361427 | ENST00000375238 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - |
| 5CDS-5UTR | ENST00000361427 | ENST00000606525 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - |
| intron-3CDS | ENST00000493418 | ENST00000246190 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - |
| intron-3CDS | ENST00000493418 | ENST00000375238 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - |
| intron-5UTR | ENST00000493418 | ENST00000606525 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000361427 | HMGN2 | chr1 | 26799118 | + | ENST00000246190 | NECAB3 | chr20 | 32248201 | - | 1655 | 109 | 94 | 912 | 272 |
| ENST00000361427 | HMGN2 | chr1 | 26799118 | + | ENST00000375238 | NECAB3 | chr20 | 32248201 | - | 1553 | 109 | 94 | 810 | 238 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000361427 | ENST00000246190 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - | 0.25794798 | 0.742052 |
| ENST00000361427 | ENST00000375238 | HMGN2 | chr1 | 26799118 | + | NECAB3 | chr20 | 32248201 | - | 0.07079637 | 0.9292036 |
Top |
Fusion Genomic Features for HMGN2-NECAB3 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for HMGN2-NECAB3 |
| Go to FGviewer for the breakpoints of chr1:26799118-chr20:32248201 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| HMGN2 | NECAB3 |
| FUNCTION: Binds to the inner side of the nucleosomal DNA thus altering the interaction between the DNA and the histone octamer. May be involved in the process which maintains transcribable genes in a unique chromatin conformation (By similarity). {ECO:0000250}. | FUNCTION: Inhibits the interaction of APBA2 with amyloid-beta precursor protein (APP), and hence allows formation of amyloid-beta. May enhance the activity of HIF1A and thus promote glycolysis under normoxic conditions; the function requires its ABM domain and may implicate the stabilization of the interaction between HIF1AN and APBA3. {ECO:0000269|PubMed:10833507, ECO:0000269|PubMed:26948053}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | NECAB3 | chr1:26799118 | chr20:32248201 | ENST00000246190 | 4 | 12 | 296_385 | 129.0 | 397.0 | Domain | Note=ABM | |
| Tgene | NECAB3 | chr1:26799118 | chr20:32248201 | ENST00000375238 | 4 | 13 | 296_385 | 129.0 | 363.0 | Domain | Note=ABM |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | NECAB3 | chr1:26799118 | chr20:32248201 | ENST00000246190 | 4 | 12 | 49_60 | 129.0 | 397.0 | Calcium binding | Ontology_term=ECO:0000255 | |
| Tgene | NECAB3 | chr1:26799118 | chr20:32248201 | ENST00000375238 | 4 | 13 | 49_60 | 129.0 | 363.0 | Calcium binding | Ontology_term=ECO:0000255 | |
| Tgene | NECAB3 | chr1:26799118 | chr20:32248201 | ENST00000246190 | 4 | 12 | 36_71 | 129.0 | 397.0 | Domain | EF-hand | |
| Tgene | NECAB3 | chr1:26799118 | chr20:32248201 | ENST00000375238 | 4 | 13 | 36_71 | 129.0 | 363.0 | Domain | EF-hand |
Top |
Fusion Gene Sequence for HMGN2-NECAB3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000361427_ENST00000246190_ERR315404_HMGN2_chr1_26799118_+_NECAB3_chr20_32248201_length(transcript)=1655nt_BP=109nt AAGAGGCGAGAACGACCCCCGGACCGACCAAAGCCCGCGCGCCGCTGCATCCCGCGTCCAGCACCTACGTCCCGCTGCCGTCGCCGCCGC CACCATGCCCAAGAGAAAGGAGTACGAGAGGGCCTCCAAAGTGGACCAGTTTGTGACGCGCTTCCTGCTGCGGGAGACGGTGAGCCAGCT GCAAGCCCTTCAGAGCTCGCTGGAGGGGGCGTCAGATACCCTGGAGGCCCAGGCCCATGGCTGGCGGTCAGATGCAGAGAGCGTGGAGGC GCAGAGCAGGCTCTGCGGCAGCCGGCGGGCAGGACGCCGAGCCCTGAGGAGTGTCAGCCGGTCATCCACCTGGTCCCCCGGCTCTTCTGA CACAGGGCGCAGCTCAGAGGCCGAGATGCAGTGGCGGCTCCAGGTGAACCGCCTCCAGGAGCTCATCGACCAGCTCGAGTGCAAGGTGAG GGCCGTGGGGCCAGGGCCCCACAAGGGAGGACCCTCCTGGTATCCACCAGAGCCAGGCCCATGCTGGAGGCCCGGCCCACACTCTGTGCC CTCACAGGCCCCCCGGCTGGAACCCCTGCGTGAAGAGGACCTGGCCAAGGGGCCTGACTTGCACATCCTCATGGCCCAGAGGCAGGTCCA GGTGGCAGAGGAAGGCCTGCAGGACTTCCACCGAGCCCTGCGCTGCTATGTGGACTTCACAGGGGCCCAGAGCCATTGTCTGCATGTGTC CGCCCAGAAGATGCTGGACGGTGCCTCCTTCACCCTGTATGAGTTCTGGCAGGATGAGGCCTCCTGGAGAAGGCACCAGCAGTCGCCTGG CAGCAAGGCCTTCCAGCGCATCCTCATCGACCACCTGCGGGCCCCGGACACCCTCACCACTGTGTTCTTCCCAGCCTCCTGGTGGATAAT GAATAACAACTGAGCCAGACCTGCACACGCCGAGGGCCCCGGGACCCTGCCTGCCTCCCTCTGGAGCCTTCTGGACTGGCCAGCCCAGCG CAAAGACCAGGACTTGTCTCCTCCTGGACTTGGGCCTGGTGGAAGGGCTCTCAGCCCAGGGATCAGGGACTGGGCTGCTTGCTTTCTATT TATTATTGATTTATTTATCCCTGTATTTTATTGTTTGTCACTTCAGCCTCCAAGCTACTTTGGCTTCTGCCTGGCTCAGGAGACCTGGAT TCTGGTCCCTGCTGTCCCTGCCTGGCTGAGCGACCCAGGGCAGGTCCCGTCCCTGTCTGGGTGGGCCTCAGGCCATCTGGCCGCCTAGCG AGGGTCCTGCTTTCTTCCTGCTGTCTTGGGACCAGGCTTCTGCTCCTCCTCAGCCAGCGGCAGAAGCAGGGCTGATGCTCAGGGACCCCC CAACCCTCAAACCTTGCCTCCGAGGCTGGGCCTGAGCTGGGTGCCCCGTCGCCCTCCCAGGCCACTAGGCTCTGACTCTTCCAGCACCCA TGGATGTGCCAGAGGCCTCTGGGTTGGTTTGCATGTCATTTGCATATCGTTTGCATGCCCTCATCCCACCCATTCTCAGGGCAGTATGGG AAGCCCCAAGGTGACCTGGCCAAGTAGCAATAATTTGGGTCCAGGGTCACCTATTGCCCCCAGAGGCCTCTGAACCCCAGGCTGGGACCC >In-frame_ENST00000361427_ENST00000246190_ERR315404_HMGN2_chr1_26799118_+_NECAB3_chr20_32248201_length(amino acids)=272AA_start in transcript=94_stop in transcript=912 MPKRKEYERASKVDQFVTRFLLRETVSQLQALQSSLEGASDTLEAQAHGWRSDAESVEAQSRLCGSRRAGRRALRSVSRSSTWSPGSSDT GRSSEAEMQWRLQVNRLQELIDQLECKVRAVGPGPHKGGPSWYPPEPGPCWRPGPHSVPSQAPRLEPLREEDLAKGPDLHILMAQRQVQV AEEGLQDFHRALRCYVDFTGAQSHCLHVSAQKMLDGASFTLYEFWQDEASWRRHQQSPGSKAFQRILIDHLRAPDTLTTVFFPASWWIMN -------------------------------------------------------------- >In-frame_ENST00000361427_ENST00000375238_ERR315404_HMGN2_chr1_26799118_+_NECAB3_chr20_32248201_length(transcript)=1553nt_BP=109nt AAGAGGCGAGAACGACCCCCGGACCGACCAAAGCCCGCGCGCCGCTGCATCCCGCGTCCAGCACCTACGTCCCGCTGCCGTCGCCGCCGC CACCATGCCCAAGAGAAAGGAGTACGAGAGGGCCTCCAAAGTGGACCAGTTTGTGACGCGCTTCCTGCTGCGGGAGACGGTGAGCCAGCT GCAAGCCCTTCAGAGCTCGCTGGAGGGGGCGTCAGATACCCTGGAGGCCCAGGCCCATGGCTGGCGGTCAGATGCAGAGAGCGTGGAGGC GCAGAGCAGGCTCTGCGGCAGCCGGCGGGCAGGACGCCGAGCCCTGAGGAGTGTCAGCCGGTCATCCACCTGGTCCCCCGGCTCTTCTGA CACAGGGCGCAGCTCAGAGGCCGAGATGCAGTGGCGGCTCCAGGTGAACCGCCTCCAGGAGCTCATCGACCAGCTCGAGTGCAAGGCCCC CCGGCTGGAACCCCTGCGTGAAGAGGACCTGGCCAAGGGGCCTGACTTGCACATCCTCATGGCCCAGAGGCAGGTCCAGGTGGCAGAGGA AGGCCTGCAGGACTTCCACCGAGCCCTGCGCTGCTATGTGGACTTCACAGGGGCCCAGAGCCATTGTCTGCATGTGTCCGCCCAGAAGAT GCTGGACGGTGCCTCCTTCACCCTGTATGAGTTCTGGCAGGATGAGGCCTCCTGGAGAAGGCACCAGCAGTCGCCTGGCAGCAAGGCCTT CCAGCGCATCCTCATCGACCACCTGCGGGCCCCGGACACCCTCACCACTGTGTTCTTCCCAGCCTCCTGGTGGATAATGAATAACAACTG AGCCAGACCTGCACACGCCGAGGGCCCCGGGACCCTGCCTGCCTCCCTCTGGAGCCTTCTGGACTGGCCAGCCCAGCGCAAAGACCAGGA CTTGTCTCCTCCTGGACTTGGGCCTGGTGGAAGGGCTCTCAGCCCAGGGATCAGGGACTGGGCTGCTTGCTTTCTATTTATTATTGATTT ATTTATCCCTGTATTTTATTGTTTGTCACTTCAGCCTCCAAGCTACTTTGGCTTCTGCCTGGCTCAGGAGACCTGGATTCTGGTCCCTGC TGTCCCTGCCTGGCTGAGCGACCCAGGGCAGGTCCCGTCCCTGTCTGGGTGGGCCTCAGGCCATCTGGCCGCCTAGCGAGGGTCCTGCTT TCTTCCTGCTGTCTTGGGACCAGGCTTCTGCTCCTCCTCAGCCAGCGGCAGAAGCAGGGCTGATGCTCAGGGACCCCCCAACCCTCAAAC CTTGCCTCCGAGGCTGGGCCTGAGCTGGGTGCCCCGTCGCCCTCCCAGGCCACTAGGCTCTGACTCTTCCAGCACCCATGGATGTGCCAG AGGCCTCTGGGTTGGTTTGCATGTCATTTGCATATCGTTTGCATGCCCTCATCCCACCCATTCTCAGGGCAGTATGGGAAGCCCCAAGGT GACCTGGCCAAGTAGCAATAATTTGGGTCCAGGGTCACCTATTGCCCCCAGAGGCCTCTGAACCCCAGGCTGGGACCCCAGCACAGAGGC >In-frame_ENST00000361427_ENST00000375238_ERR315404_HMGN2_chr1_26799118_+_NECAB3_chr20_32248201_length(amino acids)=238AA_start in transcript=94_stop in transcript=810 MPKRKEYERASKVDQFVTRFLLRETVSQLQALQSSLEGASDTLEAQAHGWRSDAESVEAQSRLCGSRRAGRRALRSVSRSSTWSPGSSDT GRSSEAEMQWRLQVNRLQELIDQLECKAPRLEPLREEDLAKGPDLHILMAQRQVQVAEEGLQDFHRALRCYVDFTGAQSHCLHVSAQKML -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for HMGN2-NECAB3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for HMGN2-NECAB3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for HMGN2-NECAB3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies